Abstract Overactive phosphoinositide 3-kinase (PI3K) in cancer and immune dysregulation
has spurred extensive efforts to develop therapeutic PI3K inhibitors. Although progress has …

Abstract Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR)
signaling is one of the most important intracellular pathways, which can be considered as a …

The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway
which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian …

Acute myeloid leukemia (AML) is a heterogeneous group of diseases characterized by
uncontrolled proliferation of hematopoietic stem cells in the bone marrow. Malignant cell …

Despite development of novel agents targeting oncogenic pathways, matching targeted
therapies to the genetic status of individual tumors is proving to be a daunting task for …

Acute myeloid leukaemia (AML) is a disorder characterized by a clonal proliferation derived
from primitive haematopoietic stem cells or progenitor cells. Abnormal differentiation of …

There are ample genetic and laboratory studies that suggest the PI3K–Akt pathway is vital to
the growth and survival of cancer cells. Inhibitors targeting this pathway are entering the …

The phosphatidylinositol 3-kinase (PI3K) signaling axis impacts on cancer cell growth,
survival, motility, and metabolism. This pathway is activated by several different mechanisms …

Evolving studies with several different targeted therapeutic agents are demonstrating that
patients with genomic alterations of the target, including amplification, translocation and …

Targeted therapy with imatinib in chronic myeloid leukemia (CML) prompted a new
treatment paradigm. Unlike CML, chronic lymphocytic leukemia (CLL) lacks an aberrant …